𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical evaluation of alprazolam in patients with panic disorder: A double-blind comparison with imipramine

✍ Scribed by U. Lepola; H. Heikkinen; R. Rimón; P. Riekkinen

Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
404 KB
Volume
5
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

The antipanic effect and tolerability of alprazolam and imipramine were compared during 9 weeks in 55 inpatients with panic disorder with or without agoraphobia. Both drugs decreased significantly the frequency of panic attacks, alprazolam as early as 3 weeks of treatment. The symptoms of generalized anxiety and depression decreased similarly in both groups. The tolerability of alprazolam appeared slightly better than that of imipramine. Drug-induced anticholinergic side-effects were more frequent in the imipramine group,whereas sedation, impotency, and myoclonic jerks appeared more often in the alprazolam group.

📜 SIMILAR VOLUMES

Efficacy of Venlafaxine ER in patients w
Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine
✍ Christer Allgulander; Richard Mangano; Jun Zhang; Alv A. Dahl; Ulla Lepola; Inge 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 2 views

## Abstract This study evaluated the anxiolytic efficacy, safety and tolerability of a flexible dose of venlafaxine extended release (ER) compared with placebo and paroxetine in the short‐term treatment of generalized social anxiety disorder (SAD). Adult outpatients with generalized SAD (__n__ = 43

A double-blind dose-finding study of rol
A double-blind dose-finding study of rolipram in patients with major depressive disorder
✍ E. H. Bennie; S. K. Chakravarti; C. M. B. Jarman; K. Khan; D. Master; G. H. Murr 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 460 KB 👁 2 views

Rolipram improves signal transmission in central noradrenergic neurones with a novel mechanism of action: enhanced noradrenaline (first messenger) synthesis and release, and inhibition of cAMP (second messenger) breakdown. Several comparative trials to prove antidepressant activity are under way. Re

A double-blind comparison of the efficac
A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia
✍ Cornelius L. E. Katona; Brian N. Hunter; Julia Bray 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 2 views

Objectives. To compare the ecacy of paroxetine and imipramine prospectively in patients with coexisting depression and dementia. Methods. An 8-week, double-blind, parallel group trial comparing paroxetine 20±40 mg/day with imipramine 50±100 mg/day in 198 patients aged 60 years or over with a Montgo

A Double-Blind Comparison of Sertraline
A Double-Blind Comparison of Sertraline and Imipramine in Outpatients with Major Depression: Acute (8 Weeks) and Continuation (16 Weeks) Treatment
✍ J.-P. FOURNIER; R. M. LANE; G. CHOUINARD; D. B. WATSON; M. AMIN; R. A. REMICK; L 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 2 views

In a double-blind multicentre trial in patients with major depression, the ecacy and the tolerability of sertraline were compared to those of imipramine, during an 8-week acute treatment phase followed by a 16-week continuation treatment phase in treatment responders. A total of 104 patients who met

Double-blind, placebo-controlled compari
Double-blind, placebo-controlled comparison of zolpidem, triazolam, and temazepam in elderly patients with insomnia
✍ Ilo E. Leppik; G. Barbara Roth-Schechter; G. William Gray; Martin A. Cohn; Dougl 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

Sleep disturbances and need for hypnotics are disproportionately greater in the elderly compared to younger adults. The present study provides a placebo-controlled subjective hypnotic efficacy of zolpidem, triazolam, and temazepam in elderly insomniacs. After a single-blind placebo screening week (D

A double-blind, multicenter trial compar
A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder
✍ Lesley M. Arnold; Yili Lu; Leslie J. Crofford; Madelaine Wohlreich; Michael J. D 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Abstract ## Objective To assess the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in subjects with primary fibromyalgia, with or without current major depressive disorder. ## Methods This study was a randomized, double‐blind, placebo‐controlled trial co